ScanSource (SCSC) Q1 2027 Earnings Call Transcript

ScanSource’s fiscal Q1 net sales rose 30.1% year over year to $962.3 million, but non-GAAP diluted EPS fell to $0.86 from $1.06 and adjusted EBITDA declined 18.9% to $31.3 million as lower-margin large hardware deals compressed gross margin to 12.2% from 14.5%. Management raised FY2027 guidance to $3.8–$4.0 billion in net sales and $175–$185 million in adjusted EBITDA, including MicroAge, acquired for $217.8 million net cash; it reaffirmed at least $85 million in full-year free cash flow. Q1 free cash flow was negative $44.1 million, and results also included a $4.5 million increase in bad debt expense primarily tied to Oi SA in Brazil.

Analysis

The key issue is conversion, not demand: hardware-led growth is adding revenue faster than gross profit, while higher receivables have consumed cash. Management attributes most of the margin pressure to deal timing, but that remains a hypothesis until the next quarter shows gross-margin recovery and cash conversion. Pricing is also a quality-of-growth risk: management said it contributed meaningfully, but could not isolate the amount, leaving unit demand and sustainable economics unclear.

For SCSC, the upside case is that large deals normalize, MicroAge adds higher-value services, and disruption after TD SYNNEX’s BlueStar acquisition creates share gains. The counterpoint: Intelisys’ organic growth remains modest, and partner recruitment has a 6–18 month monetization lag; the AI/services pilot is an option, not yet an earnings driver. SNX may face integration friction at BlueStar, but its broader scale could also strengthen supplier leverage—so disruption is not automatically a durable SCSC win.

Near term, the raised outlook and North American demand can support sentiment. Over 1–3 months, the test is whether margins rebound without relying on acquisition contribution. Over 6–18 months, recurring services growth and MicroAge cross-selling determine whether SCSC earns a better-quality multiple. The contrarian risk is that investors dismiss margin and cash-flow deterioration as temporary before the evidence is in; the contrarian upside is that the quarter’s deal mix may overstate normalized pressure. Falsifiers: another quarter of weak gross-profit conversion, failure to deliver the full-year free-cash-flow floor, or Intelisys net-billings growth failing to accelerate.

Key Decisions for Investors

• Do not chase the headline sales growth. Keep SCSC on a catalyst watch; consider a modest long only after the next report confirms gross-margin recovery and positive cash conversion, with a thesis stop if either deteriorates again.
• Track gross profit and adjusted EBITDA against sales, not revenue alone; request a bridge separating deal mix, pricing, MicroAge contribution, and Brazil credit costs before underwriting the full-year EBITDA outlook.
• Treat BlueStar-related share gains and MicroAge AI/services cross-selling as unproven upside. Reassess after evidence of supplier or customer shifts and repeatable services revenue, rather than relying on management’s pilot or market-share expectations.
• Avoid a SCSC/SNX pair trade for now: the competitive disruption could benefit SCSC, but SNX’s scale and integration execution make the relative direction uncertain.